[go: up one dir, main page]

WO2011025167A3 - Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
WO2011025167A3
WO2011025167A3 PCT/KR2010/005336 KR2010005336W WO2011025167A3 WO 2011025167 A3 WO2011025167 A3 WO 2011025167A3 KR 2010005336 W KR2010005336 W KR 2010005336W WO 2011025167 A3 WO2011025167 A3 WO 2011025167A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
pharmaceutical composition
treating cancer
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/005336
Other languages
French (fr)
Korean (ko)
Other versions
WO2011025167A2 (en
Inventor
한동초
권병목
윤영주
이진수
유제만
성승규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Dong Wha Pharm Co Ltd
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB, Dong Wha Pharm Co Ltd filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2011025167A2 publication Critical patent/WO2011025167A2/en
Publication of WO2011025167A3 publication Critical patent/WO2011025167A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a pharmaceutical composition for preventing or treating cancer comprising a 2,6-substituted 3-nitropyridine derivative compound or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention can be used to advantage in treating cancer and preventing cancer as it effectively inhibits the growth of cancer cell lines and the activity of heat shock factor 1.
PCT/KR2010/005336 2009-08-28 2010-08-13 Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof Ceased WO2011025167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090080742A KR101630432B1 (en) 2009-08-28 2009-08-28 Pharmaceutical composition comprising 2,6-substituted 3-nitropyridine derivatives or thereof salt for preventing or treatment of cancer
KR10-2009-0080742 2009-08-28

Publications (2)

Publication Number Publication Date
WO2011025167A2 WO2011025167A2 (en) 2011-03-03
WO2011025167A3 true WO2011025167A3 (en) 2011-06-16

Family

ID=43628541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005336 Ceased WO2011025167A2 (en) 2009-08-28 2010-08-13 Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof

Country Status (2)

Country Link
KR (1) KR101630432B1 (en)
WO (1) WO2011025167A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US12098117B2 (en) 2018-12-11 2024-09-24 Duke University Compositions and methods for the treatment of cancer
CN116887866A (en) 2020-12-03 2023-10-13 巴特尔纪念研究院 Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
KR102738668B1 (en) * 2022-02-25 2024-12-06 계명대학교 산학협력단 Novel compound having anticancer and use thereof
CN115611885B (en) * 2022-08-29 2024-07-19 厦门大学 N-substituted-5- ((4-substituted pyrimidin-2-yl) amino) -1H-indole-2-carboxamide derivatives
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems
CN119798223B (en) * 2025-01-02 2025-10-24 沈阳药科大学 A (1H-indazol-5-yl)amino-2-pyridine derivative and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567272A (en) * 1983-09-21 1986-01-28 Rutgerswerke Aktiengesellschaft Pyrrole containing 2-aminonitropyridine derivatives
KR20090025371A (en) * 2006-07-01 2009-03-10 메르크 파텐트 게엠베하 Indazole derivatives for the treatment of HSP90-induced diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566194B1 (en) * 1999-12-29 2006-03-29 동화약품공업주식회사 Novel 3-nitropyridine derivatives and pharmaceutical compositions comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567272A (en) * 1983-09-21 1986-01-28 Rutgerswerke Aktiengesellschaft Pyrrole containing 2-aminonitropyridine derivatives
KR20090025371A (en) * 2006-07-01 2009-03-10 메르크 파텐트 게엠베하 Indazole derivatives for the treatment of HSP90-induced diseases

Also Published As

Publication number Publication date
KR101630432B1 (en) 2016-06-15
KR20110023118A (en) 2011-03-08
WO2011025167A2 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2011025167A3 (en) Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof
WO2012047017A3 (en) 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same
WO2010021680A3 (en) Inhibitors of beta-secretase
TR201906936T4 (en) Thienopyrimidine derivatives with inhibitory activity towards protein kinase.
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2011093684A3 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
TWI562992B (en) Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
MX2012000414A (en) Pyridin-4-yl derivatives.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
IN2014KN00948A (en)
SI2324008T1 (en) 3,4-diarylpyrazoles as protein kinase inhibitors
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TW200801000A (en) Spiroindolinone derivatives
PH12012501649A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2012021796A8 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
WO2011052923A3 (en) Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
WO2010016683A3 (en) Composition for the prevention and treatment of alopecia or for hair growth
CA2881554C (en) Methods for inhibiting fascin
RU2018135973A (en) PHARMACEUTICAL COMBINATION CONTAINING METROFORMIN AND DYHYDROQUERCENINE, AND ITS APPLICATION FOR TREATING CANCER
MX341342B (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-h ydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1 h-benzimidazol-2-yl]urea.
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
EP2583962A4 (en) Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812181

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812181

Country of ref document: EP

Kind code of ref document: A2